Results 211 to 220 of about 211,384 (368)

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice

open access: yesThoracic Cancer, Volume 13, Issue 23, Page 3295-3303, December 2022., 2022
Based on real‐world practice, the continued application of immunotherapy can be an option after progression of first‐line chemotherapy plus ICIs in ES‐SCLC patients (median PFS1 + PFS2 11.27 months vs. 7.20 months, hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.14–1.51, p = 0.19).
Yaning Yang   +11 more
wiley   +1 more source

DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation. [PDF]

open access: yesJ Immunother Cancer
Fuchs KJ   +13 more
europepmc   +1 more source

PIPLOM: prediction of exogenous peptide loading on major histocompatibility complex class I molecules. [PDF]

open access: yesBioinform Adv
Schmidt F   +11 more
europepmc   +1 more source

A model system for determining histocompatibility in man

open access: bronze, 1964
R. E. Wilson, y Henr, John P. Merrill
openalex   +1 more source

Home - About - Disclaimer - Privacy